Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMG1015 in idiopathic pulmonary fibrosis
NCT05895565Phase 1Completed
- Sponsor
- Pulmongene (Hong Kong) Co., Ltd.
- Start
- May 2023
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing PMG1015 with Placebo Comparator (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events at 170 days, Severity of treatment-emergent adverse events at 170 days and 7 more. Started May 2023; status: completed.
02
Drugs
PMG1015
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05895565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895565.